Abstract:
본발명은하기화학식 (I) 및/또는 (II) (식중, R 은 6 내지 22 개의탄소원자를갖는선형또는분지형, 포화또는불포화알킬라디칼이고, X 및 Y 는각각독립적으로수소원자, 또는수용성염을형성할수 있고알칼리금속, 알칼리토금속, 암모니아및 유기암모니아로이루어지는군으로부터선택되는양이온임) 의알킬술포숙시네이트모노에스테르의혼합물에관한것이다.본발명은혼합물이 30 내지 70 중량% 의 C16 알킬술포숙시네이트모노에스테르및 30 내지 70 중량% 의 C18 알킬술포숙시네이트모노에스테르를함유하는것을특징으로하며, 이때중량% 는화학식 (I) 및 (II) 의알킬술포숙시네이트모노에스테르의총량에대한것이다. 본발명은또한미용및/또는약학제제에서의상기혼합물의용도에관한것이다.
Abstract:
Omega-3 lipid compounds of the general formula (I): wherein R1 and R2are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; P represents a hydrogen atom, (Formula II) wherein P2, P3, and P4 are chosen from a hydrogen atom, an alkyl group, and a C14-C22 alkenyl group, wherein the alkyl and alkenyl groups are optionally substituted with a hydroxy group, (Formula III), (Formula IV), or (Formula V); and Y is a C14-C22 alkenyl group with at least one double bond, having E and/or Z configuration; or any pharmaceutically acceptable complex, solvate, salt or pro-drug thereof, with the proviso that R1 and R2 are not simultaneously a hydrogen atom. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments, in particular for the treatment of cardiovascular and metabolic diseases.
Abstract:
Conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment, and methods of use, have been developed. One or more active agents, such as antivirals, antimicrobials, anti-inflammatories, proteins or peptides, may optionally be included with the formulation. The active agent may be administered with or incorporated into the formulation, or may be administered after the conductive formulation is administered. When applied to mucosal lining fluids, the formulation alters the physical properties such as the surface tension, surface elasticity, and bulk viscosity of the mucosal lining. The formulation is administered in an amount sufficient to alter biophysical properties in the mucosal linings of the body. The formulations may be administered for several different purposes: reducing the spreading of infectious diseases, both viral and bacterial, such as SARS, influenza, tuberculosis, and RSV in humans and hoof and mouth disease in cloven-footed animals; minimizing ambient contamination due to particle formation during breathing, coughing, sneezing, or talking which is particularly important in the clean room applications; decreasing or preventing the occurrence of obstructive sleep apnea and some cases of irritable bowel syndrome; and controlling the uptake kinetics of drug molecules and pathogens.
Abstract:
The present invention aims to provide for the treatment of hyperlipidemia, arteriosclerosis and hyper-remnant-emia, and to inhibit remnant lipoportein production by adminsetering an inhibitor of CEPT (cholesteryl ester transfer protein). Said inhibitor is a compound selected from the group cosisting of compounds of formula I to fomula XXIII, and compounds selected from the group consisting of JTT-705, CP- 529414, SC-795, SC-744, SC-554, SC-71952, SC-56960, SC-57201, PD-140195, WK-5341A, WK-5344B, CETI-1 (CETP Vaccine), BM99-1 and BM99-2.
Abstract:
본 발명은 지질 조절에 효과적인, 예를 들면, 술팜산, [[2,4,6-트리스(1-메틸에틸)-페닐]아세틸]-, 2,6-비스[(1-메틸에틸)페닐 에스테르와 같은 ACAT 억제제, 및 예를 들면, 아토르바스타틴과 같은 HMG-CoA 환원효소 억제제의 조합에 관한 것이다. 이러한 시약의 조합은 혈장 VLDL 및 LDL 콜레스테롤을 크게 감소시키며 어느 한 쪽 단독으로보다 HDL 콜레스테롤을 증가시켜서 아테롬 발생성 지단백질 특성을 적게 한다. 이 조합은 허혈성 증후군이 발병하거나 또는 발병의 위험이 있는 환자의 치료에서 내생적 혈관 내피 의존 활성을 회복하기 위해서 유용하다.
Abstract:
PURPOSE: Pharmaceutical compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia are provided, thereby effectively treating and preventing tumors and tumor-related disorders and cachexia by certain cyclooxygenase-2 inhibitors. CONSTITUTION: The pharmaceutical compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia comprises a compound of formula (I),(II) and pharmaceutically acceptable salts thereof, wherein R represents a hydrogen atom, a halogen atom or a lower alkyl group; R1 represents a lower alkyl group, an amino group or a group of formula -NHRa in which Ra represents a group which may be eliminated in vivo; R2 represents a phenyl group or a phenyl group which is substituted by at least one of substituents alpha or substituents beta , defined below; R3 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkyl group which is substituted by at least one of substituents alpha ; R4 represents a hydrogen atom, a lower alkyl group, a lower alkyl group which is substituted by at least one of substituents alpha, a cycloalkyl group, an aryl group.
Abstract translation:目的:提供用于治疗和预防肿瘤,肿瘤相关疾病和恶病质的药物组合物,从而有效地治疗和预防某些环加氧酶-2抑制剂的肿瘤和肿瘤相关疾病和恶病质。 构成:用于治疗和预防肿瘤,肿瘤相关疾病和恶病质的药物组合物包含式(I),(II)及其药学上可接受的盐的化合物,其中R表示氢原子,卤素原子或低级 烷基; R1表示低级烷基,氨基或式-NHRa基团,其中Ra表示可在体内被除去的基团; R 2表示苯基或被至少一个下列定义的取代基α或取代基β取代的苯基; R3表示氢原子,卤素原子,低级烷基或被至少一个取代基α取代的低级烷基; R4表示氢原子,低级烷基,被取代基α,环烷基,芳基中的至少一个取代的低级烷基。